TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2019 DA - 2019// TI - Cancer statistics, 2019 JO - CA Cancer J Clin VL - 69 UR - https://doi.org/10.3322/caac.21551 DO - 10.3322/caac.21551 ID - Siegel2019 ER - TY - JOUR AU - Sun, R. AU - Liu, Z. AU - Wang, L. AU - Lv, W. AU - Liu, J. AU - Ding, C. PY - 2015 DA - 2015// TI - Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer JO - Tumour Biol VL - 36 UR - https://doi.org/10.1007/s13277-015-3361-y DO - 10.1007/s13277-015-3361-y ID - Sun2015 ER - TY - JOUR AU - Hirsch, F. R. AU - Scagliotti, G. V. AU - Mulshine, J. L. AU - Kwon, R. AU - Curran, W. J. AU - Wu, Y. L. PY - 2017 DA - 2017// TI - Lung cancer: current therapies and new targeted treatments JO - Lancet (London, England). VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)30958-8 DO - 10.1016/S0140-6736(16)30958-8 ID - Hirsch2017 ER - TY - JOUR AU - Kunkeaw, N. AU - Lee, Y. S. AU - Im, W. R. AU - Jang, J. J. AU - Song, M. J. AU - Yang, B. PY - 2019 DA - 2019// TI - Mechanism mediated by a noncoding RNA, nc886, in the cytotoxicity of a DNA-reactive compound JO - Proc Nat Acad Sci USA VL - 116 UR - https://doi.org/10.1073/pnas.1814510116 DO - 10.1073/pnas.1814510116 ID - Kunkeaw2019 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2017 DA - 2017// TI - Cancer Statistics, 2017 JO - CA Cancer J Clin VL - 67 UR - https://doi.org/10.3322/caac.21387 DO - 10.3322/caac.21387 ID - Siegel2017 ER - TY - JOUR AU - Baudino, T. A. AU - Cleveland, J. L. PY - 2001 DA - 2001// TI - The Max network gone mad JO - Mol Cell Biol VL - 21 UR - https://doi.org/10.1128/MCB.21.3.691-702.2001 DO - 10.1128/MCB.21.3.691-702.2001 ID - Baudino2001 ER - TY - JOUR AU - Siddik, Z. H. PY - 2003 DA - 2003// TI - Cisplatin: mode of cytotoxic action and molecular basis of resistance JO - Oncogene. VL - 22 UR - https://doi.org/10.1038/sj.onc.1206933 DO - 10.1038/sj.onc.1206933 ID - Siddik2003 ER - TY - JOUR AU - Dasari, S. AU - Tchounwou, P. B. PY - 2014 DA - 2014// TI - Cisplatin in cancer therapy: molecular mechanisms of action JO - European J pharmacol VL - 740 UR - https://doi.org/10.1016/j.ejphar.2014.07.025 DO - 10.1016/j.ejphar.2014.07.025 ID - Dasari2014 ER - TY - JOUR AU - O’Byrne, K. J. AU - Barr, M. P. AU - Gray, S. G. PY - 2011 DA - 2011// TI - The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer JO - Cancers. VL - 3 UR - https://doi.org/10.3390/cancers3011426 DO - 10.3390/cancers3011426 ID - O’Byrne2011 ER - TY - JOUR AU - More, S. S. AU - Akil, O. AU - Ianculescu, A. G. AU - Geier, E. G. AU - Lustig, L. R. AU - Giacomini, K. M. PY - 2010 DA - 2010// TI - Role of the copper transporter, CTR1, in platinum-induced ototoxicity JO - J Neurosci VL - 30 UR - https://doi.org/10.1523/JNEUROSCI.1544-10.2010 DO - 10.1523/JNEUROSCI.1544-10.2010 ID - More2010 ER - TY - JOUR AU - Galluzzi, L. AU - Vitale, I. AU - Michels, J. AU - Brenner, C. AU - Szabadkai, G. AU - Harel-Bellan, A. PY - 2014 DA - 2014// TI - Systems biology of cisplatin resistance: past, present and future JO - Cell Death Dis VL - 5 UR - https://doi.org/10.1038/cddis.2013.428 DO - 10.1038/cddis.2013.428 ID - Galluzzi2014 ER - TY - JOUR AU - Fong, W. F. AU - Wang, C. AU - Zhu, G. Y. AU - Leung, C. H. AU - Yang, M. S. AU - Cheung, H. Y. PY - 2007 DA - 2007// TI - Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract JO - Phytomedicine VL - 14 UR - https://doi.org/10.1016/j.phymed.2006.03.004 DO - 10.1016/j.phymed.2006.03.004 ID - Fong2007 ER - TY - JOUR AU - Chen, Z. S. AU - Kawabe, T. AU - Ono, M. AU - Aoki, S. AU - Sumizawa, T. AU - Furukawa, T. PY - 1999 DA - 1999// TI - Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter JO - Mol Pharmacol. VL - 56 UR - https://doi.org/10.1124/mol.56.6.1219 DO - 10.1124/mol.56.6.1219 ID - Chen1999 ER - TY - JOUR AU - Fujii, R. AU - Mutoh, M. AU - Sumizawa, T. AU - Chen, Z. S. AU - Yoshimura, A. AU - Akiyama, S. PY - 1994 DA - 1994// TI - Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells JO - J Nat Cancer Institute. VL - 86 UR - https://doi.org/10.1093/jnci/86.23.1781 DO - 10.1093/jnci/86.23.1781 ID - Fujii1994 ER - TY - JOUR AU - Gentile, F. AU - Tuszynski, J. A. AU - Barakat, K. H. PY - 2016 DA - 2016// TI - New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy JO - J Mol Graphics Modelling. VL - 65 UR - https://doi.org/10.1016/j.jmgm.2016.02.010 DO - 10.1016/j.jmgm.2016.02.010 ID - Gentile2016 ER - TY - JOUR AU - Liu, J. L. AU - Wang, Y. AU - Jiang, J. AU - Kong, R. AU - Yang, Y. M. AU - Ji, H. F. PY - 2010 DA - 2010// TI - Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA JO - Chinese Med J VL - 123 ID - Liu2010 ER - TY - JOUR AU - Qu, Y. AU - Xia, P. AU - Zhang, S. AU - Pan, S. AU - Zhao, J. PY - 2015 DA - 2015// TI - Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin JO - Oncol Rep VL - 33 UR - https://doi.org/10.3892/or.2014.3698 DO - 10.3892/or.2014.3698 ID - Qu2015 ER - TY - JOUR AU - Galluzzi, L. AU - Senovilla, L. AU - Vitale, I. AU - Michels, J. AU - Martins, I. AU - Kepp, O. PY - 2012 DA - 2012// TI - Molecular mechanisms of cisplatin resistance JO - Oncogene. VL - 31 UR - https://doi.org/10.1038/onc.2011.384 DO - 10.1038/onc.2011.384 ID - Galluzzi2012 ER - TY - STD TI - Chan D, Zhou Y, Chui CH, Lam KH, Law S, Chan AS, et al. Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma. Cells. 2018;7(10):143–58. ID - ref19 ER - TY - JOUR AU - Sen, T. AU - Tong, P. AU - Stewart, C. A. AU - Cristea, S. AU - Valliani, A. AU - Shames, D. S. PY - 2017 DA - 2017// TI - CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3409 DO - 10.1158/0008-5472.CAN-16-3409 ID - Sen2017 ER - TY - JOUR AU - Socinski, M. A. AU - Jotte, R. M. AU - Cappuzzo, F. AU - Orlandi, F. AU - Stroyakovskiy, D. AU - Nogami, N. PY - 2018 DA - 2018// TI - Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC JO - N Engl J Med. VL - 378 UR - https://doi.org/10.1056/NEJMoa1716948 DO - 10.1056/NEJMoa1716948 ID - Socinski2018 ER - TY - JOUR AU - Frochaux, V. AU - Hildebrand, D. AU - Talke, A. AU - Linscheid, M. W. AU - Schlüter, H. PY - 2014 DA - 2014// TI - Alpha-1-antitrypsin: a novel human high temperature requirement protease A1 (HTRA1) substrate in human placental tissue JO - PloS one. VL - 9 UR - https://doi.org/10.1371/journal.pone.0109483 DO - 10.1371/journal.pone.0109483 ID - Frochaux2014 ER - TY - JOUR AU - Campioni, M. AU - Severino, A. AU - Manente, L. AU - Tuduce, I. L. AU - Toldo, S. AU - Caraglia, M. PY - 2010 DA - 2010// TI - The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein JO - Mol Cancer Res VL - 8 UR - https://doi.org/10.1158/1541-7786.MCR-09-0473 DO - 10.1158/1541-7786.MCR-09-0473 ID - Campioni2010 ER - TY - JOUR AU - Xiong, Z. AU - Fu, Z. AU - Shi, J. AU - Jiang, X. AU - Wan, H. PY - 2017 DA - 2017// TI - HtrA1 Down-regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway JO - Ann clin lab Sci VL - 47 ID - Xiong2017 ER - TY - JOUR AU - Wang, N. AU - Eckert, K. A. AU - Zomorrodi, A. R. AU - Xin, P. AU - Pan, W. AU - Shearer, D. A. PY - 2012 DA - 2012// TI - Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathways JO - PloS one. VL - 7 UR - https://doi.org/10.1371/journal.pone.0039446 DO - 10.1371/journal.pone.0039446 ID - Wang2012 ER - TY - JOUR AU - Zurawa-Janicka, D. AU - Skorko-Glonek, J. AU - Lipinska, B. PY - 2010 DA - 2010// TI - HtrA proteins as targets in therapy of cancer and other diseases JO - Exp Opin Therapeutic targets VL - 14 UR - https://doi.org/10.1517/14728222.2010.487867 DO - 10.1517/14728222.2010.487867 ID - Zurawa-Janicka2010 ER - TY - JOUR AU - Ikushima, H. AU - Miyazono, K. PY - 2010 DA - 2010// TI - TGFbeta signalling: a complex web in cancer progression JO - Nature Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2853 DO - 10.1038/nrc2853 ID - Ikushima2010 ER - TY - JOUR AU - Oka, C. AU - Tsujimoto, R. AU - Kajikawa, M. AU - Koshiba-Takeuchi, K. AU - Ina, J. AU - Yano, M. PY - 2004 DA - 2004// TI - HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins JO - Development (Cambridge, England) VL - 131 UR - https://doi.org/10.1242/dev.00999 DO - 10.1242/dev.00999 ID - Oka2004 ER - TY - JOUR AU - Chien, J. AU - Aletti, G. AU - Baldi, A. AU - Catalano, V. AU - Muretto, P. AU - Keeney, G. L. PY - 2006 DA - 2006// TI - Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity JO - J Clin Invest VL - 116 UR - https://doi.org/10.1172/JCI27698 DO - 10.1172/JCI27698 ID - Chien2006 ER - TY - JOUR AU - He, X. AU - Khurana, A. AU - Maguire, J. L. AU - Chien, J. AU - Shridhar, V. PY - 2012 DA - 2012// TI - HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation JO - Int J Cancer VL - 130 UR - https://doi.org/10.1002/ijc.26044 DO - 10.1002/ijc.26044 ID - He2012 ER - TY - JOUR AU - Simpson, C. D. AU - Anyiwe, K. AU - Schimmer, A. D. PY - 2008 DA - 2008// TI - Anoikis resistance and tumor metastasis JO - Cancer Lett VL - 272 UR - https://doi.org/10.1016/j.canlet.2008.05.029 DO - 10.1016/j.canlet.2008.05.029 ID - Simpson2008 ER - TY - JOUR AU - Skorko-Glonek, J. AU - Zurawa-Janicka, D. AU - Koper, T. AU - Jarzab, M. AU - Figaj, D. AU - Glaza, P. PY - 2013 DA - 2013// TI - HtrA protease family as therapeutic targets JO - Curr Pharmaceutical Design VL - 19 UR - https://doi.org/10.2174/1381612811319060003 DO - 10.2174/1381612811319060003 ID - Skorko-Glonek2013 ER - TY - JOUR AU - Xu, Y. AU - Jiang, Z. AU - Zhang, Z. AU - Sun, N. AU - Zhang, M. AU - Xie, J. PY - 2014 DA - 2014// TI - HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties JO - J Cell Biochem VL - 115 UR - https://doi.org/10.1002/jcb.24751 DO - 10.1002/jcb.24751 ID - Xu2014 ER - TY - JOUR AU - IJ, A. AU - Tan, N. S. AU - Gelman, L. AU - Kersten, S. AU - Seydoux, J. AU - Xu, J. PY - 2004 DA - 2004// TI - In vivo activation of PPAR target genes by RXR homodimers JO - EMBO J VL - 23 UR - https://doi.org/10.1038/sj.emboj.7600209 DO - 10.1038/sj.emboj.7600209 ID - IJ2004 ER - TY - JOUR AU - Wang, L. AU - Chen, G. AU - Chen, K. AU - Ren, Y. AU - Li, H. AU - Jiang, X. PY - 2015 DA - 2015// TI - Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.3149 DO - 10.18632/oncotarget.3149 ID - Wang2015 ER - TY - JOUR AU - Schmidt, N. AU - Irle, I. AU - Ripkens, K. AU - Lux, V. AU - Nelles, J. AU - Johannes, C. PY - 2016 DA - 2016// TI - Epigenetic silencing of serine protease HTRA1 drives polyploidy JO - BMC cancer. VL - 16 UR - https://doi.org/10.1186/s12885-016-2425-8 DO - 10.1186/s12885-016-2425-8 ID - Schmidt2016 ER - TY - JOUR AU - Mi, W. AU - Guan, H. AU - Lyu, J. AU - Zhao, D. AU - Xi, Y. AU - Jiang, S. PY - 2017 DA - 2017// TI - YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer JO - Nat Commun. VL - 8 UR - https://doi.org/10.1038/s41467-017-01173-4 DO - 10.1038/s41467-017-01173-4 ID - Mi2017 ER - TY - JOUR AU - Witt, O. AU - Deubzer, H. E. AU - Milde, T. AU - Oehme, I. PY - 2009 DA - 2009// TI - HDAC family: What are the cancer relevant targets? JO - Cancer Lett VL - 277 UR - https://doi.org/10.1016/j.canlet.2008.08.016 DO - 10.1016/j.canlet.2008.08.016 ID - Witt2009 ER - TY - JOUR AU - Wang, L. AU - Li, H. AU - Ren, Y. AU - Zou, S. AU - Fang, W. AU - Jiang, X. PY - 2016 DA - 2016// TI - Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms JO - Cell Death Dis VL - 7 UR - https://doi.org/10.1038/cddis.2015.328 DO - 10.1038/cddis.2015.328 ID - Wang2016 ER - TY - JOUR AU - Wang, L. AU - Liu, X. AU - Ren, Y. AU - Zhang, J. AU - Chen, J. AU - Zhou, W. PY - 2017 DA - 2017// TI - Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity JO - Cell Death Dis VL - 8 UR - https://doi.org/10.1038/cddis.2016.409 DO - 10.1038/cddis.2016.409 ID - Wang2017 ER - TY - JOUR AU - Huffman, K. AU - Martinez, E. D. PY - 2013 DA - 2013// TI - Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer JO - Front Oncol VL - 3 UR - https://doi.org/10.3389/fonc.2013.00235 DO - 10.3389/fonc.2013.00235 ID - Huffman2013 ER - TY - JOUR AU - Zuco, V. AU - Cassinelli, G. AU - Cossa, G. AU - Gatti, L. AU - Favini, E. AU - Tortoreto, M. PY - 2015 DA - 2015// TI - Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor JO - Biochem Pharmacol VL - 94 UR - https://doi.org/10.1016/j.bcp.2015.01.002 DO - 10.1016/j.bcp.2015.01.002 ID - Zuco2015 ER - TY - JOUR AU - Perego, P. AU - Zuco, V. AU - Gatti, L. AU - Zunino, F. PY - 2012 DA - 2012// TI - Sensitization of tumor cells by targeting histone deacetylases JO - Biochem Pharmacol VL - 83 UR - https://doi.org/10.1016/j.bcp.2011.11.010 DO - 10.1016/j.bcp.2011.11.010 ID - Perego2012 ER - TY - JOUR AU - Wang, L. H. AU - Jiang, X. R. AU - Chen, G. L. AU - Guo, W. AU - Zhang, J. Y. AU - Cui, L. J. PY - 2016 DA - 2016// TI - Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway JO - Scientific Rep VL - 6 UR - https://doi.org/10.1038/srep36486 DO - 10.1038/srep36486 ID - Wang2016 ER - TY - JOUR AU - Hansen, N. J. AU - Wylie, R. C. AU - Phipps, S. M. AU - Love, W. K. AU - Andrews, L. G. PY - 2007 DA - 2007// TI - The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells JO - Int J Oncol. VL - 30 ID - Hansen2007 ER - TY - JOUR AU - Tooker, P. AU - Yen, W. C. AU - Ng, S. C. AU - Negro-Vilar, A. AU - Hermann, T. W. PY - 2007 DA - 2007// TI - Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-4495 DO - 10.1158/0008-5472.CAN-06-4495 ID - Tooker2007 ER - TY - JOUR AU - Yen, W. C. AU - Corpuz, M. R. AU - Prudente, R. Y. AU - Cooke, T. A. AU - Bissonnette, R. P. AU - Negro-Vilar, A. PY - 2004 DA - 2004// TI - A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0979 DO - 10.1158/1078-0432.CCR-04-0979 ID - Yen2004 ER - TY - JOUR AU - Willson, T. M. AU - Brown, P. J. AU - Sternbach, D. D. AU - Henke, B. R. PY - 2000 DA - 2000// TI - The PPARs: from orphan receptors to drug discovery JO - J Med Chem VL - 43 UR - https://doi.org/10.1021/jm990554g DO - 10.1021/jm990554g ID - Willson2000 ER - TY - JOUR AU - Dawson, M. I. AU - Xia, Z. PY - 2012 DA - 2012// TI - The retinoid X receptors and their ligands JO - Biochimica et biophysica acta. VL - 1821 UR - https://doi.org/10.1016/j.bbalip.2011.09.014 DO - 10.1016/j.bbalip.2011.09.014 ID - Dawson2012 ER - TY - JOUR AU - Blandino, G. AU - Agostino, S. PY - 2018 DA - 2018// TI - New therapeutic strategies to treat human cancers expressing mutant p53 proteins JO - J Exp Clin Cancer Res VL - 37 UR - https://doi.org/10.1186/s13046-018-0705-7 DO - 10.1186/s13046-018-0705-7 ID - Blandino2018 ER - TY - JOUR AU - Lusche, D. F. AU - Buchele, E. C. AU - Russell, K. B. AU - Soll, B. A. AU - Vitolo, M. I. AU - Klemme, M. R. PY - 2018 DA - 2018// TI - Overexpressing TPTE2 (TPIP), a homolog of the human tumor suppressor gene PTEN, rescues the abnormal phenotype of the PTEN(−/−) mutant JO - Oncotarget. VL - 9 UR - https://doi.org/10.18632/oncotarget.24941 DO - 10.18632/oncotarget.24941 ID - Lusche2018 ER - TY - STD TI - Dasgupta A, Nomura M, Shuck R, Yustein J. Cancer’s Achilles’ Heel: Apoptosis and Necroptosis to the Rescue. Int J Mol Sci. 2016;18(1):23–43. ID - ref52 ER -